Provided by Tiger Trade Technology Pte. Ltd.

Genprex, Inc.

3.95
0.0000
Post-market: 3.950.00000.00%19:58 EDT
Volume:96.48K
Turnover:390.69K
Market Cap:3.24M
PE:-0.02
High:4.29
Open:3.90
Low:3.86
Close:3.95
52wk High:1,210.00
52wk Low:3.83
Shares:819.70K
Float Shares:818.70K
Volume Ratio:0.09
T/O Rate:11.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-173.0075
EPS(LYR):-382.7870
ROE:-203.86%
ROA:-94.46%
PB:0.22
PE(LYR):-0.01

Loading ...

Genprex files $250M mixed securities shelf

TIPRANKS
·
Jun 06

Genprex Inc Files for Mixed Shelf of up to $250 Mln – SEC Filing

THOMSON REUTERS
·
Jun 06

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 26

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

TIPRANKS
·
May 15

Genprex Q1 net loss widens 13% to $4.46 million year over year

Reuters
·
May 14

Genprex Receives Patent Grant From the Israel Patent Office for the Combination of Reqorsa® Gene Therapy and Pd-1 Antibodies to Treat Cancer

THOMSON REUTERS
·
Apr 30

Genprex says Israel grants patent for Reqorsa plus PD-1 antibody cancer treatment combo

Reuters
·
Apr 30

Genprex says diabetes gene therapy reverses hyperglycemia in preclinical Type 2 models

Reuters
·
Apr 28

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy to Be Released at the 2026 Asco Annual Meeting

THOMSON REUTERS
·
Apr 22

Genprex signs MD Anderson research deal to study Reqorsa lung cancer response biomarkers

Reuters
·
Apr 21

Genprex Signs Sponsored Research Agreement to Study Biomarkers That May Predict Patient Response to Reqorsa® Gene Therapy

THOMSON REUTERS
·
Apr 21

Genprex says Reqorsa gene therapy data support potential ALK+ NSCLC clinical trial

Reuters
·
Apr 20

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 Aacr Annual Meeting

THOMSON REUTERS
·
Apr 20

Genprex announces annual shareholder meeting webcast

Reuters
·
Apr 18

Genprex director Brent Longnecker disposes of USD 22 common shares

Reuters
·
Apr 16

Genprex FY25 net loss narrows 23% to $16M

Reuters
·
Mar 31

Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR 2026

Reuters
·
Mar 18

Genprex executives to attend BIO Europe Spring 2026

Reuters
·
Mar 10

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

TIPRANKS
·
Feb 23

Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies

Reuters
·
Feb 23